(Q73506602)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

L J Lesko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Rowland

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C C Peck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

T F Blaschke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

1335-1344

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche

4 November 2019

cites work

1 reference

12 December 2020

Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

Econometrics in outcomes research: the use of instrumental variables

1 reference

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

12 December 2020

Pharmacologically guided phase I clinical trials based upon preclinical drug development

1 reference

12 December 2020

Simulation of clinical trials

1 reference

12 December 2020

Pharmacokinetics, Pharmacodynamics, and Rational Opioid Selection

1 reference

12 December 2020

The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic modeling in drug development

1 reference

12 December 2020

Learning versus confirming in clinical drug development

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1007574217260

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11205725%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference